companies

TISSIUM

Founded 2013
Employees 100+
Primary contact
74 rue du Faubourg Saint-Antoine
75012 Paris
France
+33 1 7621 7228
Links
https://tissium.com/
Sections
TISSIUM is developing a portfolio of products that leverage its proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are the foundation of the company's technology platform. TISSIUM has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair, and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products. TISSIUM's technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital). In addition to France, the company also has an office in Boston.
Founded 2013
Employees 100+
Primary contact
74 rue du Faubourg Saint-Antoine
75012 Paris
France
+33 1 7621 7228
Links
https://tissium.com/
Sections

Funding 💰

Total $210M
Last round 🔗 €50M
Series D
May 23, 2023.
Select investors Cathay Capital, Sofinnova Partners, Bpifrance, CM-CIC Capital Finance, Omnes Capital, Karista, Crédit Mutuel Innovation, European Investment Fund, IBD Ventures

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Biomorphic programmable polymers: TISSIUM's proprietary biomorphic programmable polymers enable tissue reconstruction and can be adapted for use in multiple clinical areas. The "biomorphic" part means that they can conform to and integrates with surrounding tissue to enable tissue reconstruction, and "programmable" means that polymer building blocks can be adjusted to match tissue-specific requirements. 🔗
  • Therapeutic areas: Applications of TISSIUM's products include tissue sealants for use in cardiovascular procedures, tissue adhesives for use in peripheral nerve and gastrointestinal procedures, 3D-printed implants for peripheral nerve repair, and drug-eluting adhesives for the treatment of ENT diseases. 🔗
  • Achievements: As of June 2023, TISSIUM had 3 CE Marks, 64 patents granted, and 37 patents pending, while its technology and approach have been published in 9 publications.
  • Media love: During the years, TISSIUM has been featured in a few publications, including Forbes, Bloomberg, Time, Wired, National Geographic, and Business Insider, among others.

Video ▶️

Quotes 💬

“
At Sofinnova Partners, we have been convinced since the beginning of TISSIUM's potential to revolutionize tissue repair and bring a truly innovative solution for patients worldwide. We are pleased to be joined by Cathay Health and other investors who share this vision as we continue to support TISSIUM and provide the means for this exceptional team to pursue its development and prepare the commercialization of its lead products.
— Antoine Papiernik, Managing Partner at Sofinnova Partners 🔗
“
TISSIUM is creating the future of tissue reconstruction on all continents. Its expandable platform is solving for widespread problems in surgeries addressing the needs of atraumatic repairs and can be applied to multiple, large, unmet therapeutic areas. As a cross-border investment platform spanning the US, Europe and Asia, we look forward to bringing the global outlook, resources and health ecosystem to support TISSIUM's brilliant team in its international expansion and for the next steps toward commercialization and growth.
— Hongjie Hu, Co-founder and Managing Partner of Cathay Health 🔗
Last update: June 28, 2023